Cutting SARMs

Why Body Recomposition Is the Hardest Problem in Training Research

The compounds in the cut-and-lean category are studied for their ability to shift body composition by preserving or building lean tissue, promoting fat oxidation, improving metabolic efficiency, and supporting performance during a caloric deficit.

The central challenge in any cutting protocol is the same: maintaining muscle mass while reducing body fat. The compounds in this category address that problem from different mechanistic angles.

Compounds in This Category

Ostarine (MK-2866)

The most clinically researched compound in this range. A Phase 2 trial published in The Lancet Oncology found statistically significant retention of lean body mass in cancer patients with muscle wasting compared with placebo, establishing its anti-catabolic properties in a controlled human setting. [1]

Key characteristics of Ostarine:

• Mild side effect profile.
• Effective across a wide range of dosing contexts.
• Well-tolerated on cycles up to 12 weeks.
• Does not aromatise.

Cardarine (GW-501516)

Cardarine approaches body composition from the metabolic side, activating PPARdelta receptors to increase fat oxidation and shift muscle fibres toward an oxidative profile. A mouse study confirmed increased endurance and altered muscle fibre expression both with and without exercise. [2]

Important note: Cardarine is not a SARM and does not interact with androgen receptors. Its carcinogenicity findings in long-term animal studies are documented and should inform any research protocol.

Andarine (S4)

Andarine adds a harder, leaner effect through direct AR activity, with preclinical evidence from an ovariectomised rat model supporting effects on bone mineral density and body fat reduction. [3]

Dose-dependent visual disturbances, including a yellow tint to vision and reduced dark adaptation, are a documented variable linked to off-target retinal AR binding and should be factored into any study design.

Quality Assurance

All compounds are independently lab-tested, batch-traceable, and supplied with certificates of analysis. Sold strictly for research purposes. Not approved for human use.

Want to read more? Check out The Ultimate Cutting Stack: SARMs for Fat Loss.

Sources:

[1] Dobs, A. S., Boccia, R. V., Croot, C. C., et al. (2013). Effects of enobosarm on muscle wasting and physical function in patients with cancer: a double-blind, randomised controlled phase 2 trial. The Lancet Oncology, 14(4), 335-345. https://doi.org/10.1016/S1470-2045(13)70055-X

[2] Chen, W., Gao, R., Xie, X., et al. (2015). A metabolomic study of the PPARdelta agonist GW501516 for enhancing running endurance in Kunming mice. Scientific Reports, 5, 9884. https://doi.org/10.1038/srep09884

[3] Kearbey, J. D., Gao, W., Narayanan, R., et al. (2007). Selective Androgen Receptor Modulator (SARM) treatment prevents bone loss and reduces body fat in ovariectomized rats. Pharmaceutical Research, 24(2), 328-335. https://doi.org/10.1007/s11095-006-9152-9